News for FPRX Stock

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium Five Prime Announces Closing of Upsized Public Offering of Common Stock Five Prime Announces Pricing of Upsized Public Offering of Common Stock Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157 Five Prime Announces Proposed Public Offering of Common Stock Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer Five Prime Therapeutics Reports Third Quarter 2020 Results Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call